Nain Biotech (Hangzhou) Co. Ltd. has identified tetrahydrocarbazole derivatives reported to be useful for the treatment of cancer and viral infections.

Progentos Therapeutics Inc. has synthesized PDGFRα inhibitors reported to be useful for the treatment of optic neuritis and multiple sclerosis.

Foghorn Therapeutics Inc. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising ubiquitin ligase binding moieties covalently linked to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) targeting moiety reported to be useful for the treatment of cancer and viral infection.

Scientists at Inventisbio Co. Ltd. and Inventisbio LLC have divulged E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.

Oita University has synthesized tricyclic heterocyclic compounds reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

TYK Medicines Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently bonded to an EGFR (mutant)-targeting moiety through a linker.

Icagen Inc. has disclosed potassium voltage-gated channel subfamily KQT member 2 (KCNQ2; Kv7.2) activators reported to be useful for the treatment of pain, Alzheimer’s disease, epilepsy, motor neuron disease, neurodevelopmental disorders, depression, tinnitus and attention deficit hyperactivity disorder, among others.

Beijing Danatlas Pharmaceutical Technology Co. Ltd. has divulged DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has described pyrrolobenzodiazepine compounds reported to be useful for the treatment of cancer.

Amgen Inc. has synthesized GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.